By CapitalSnitch Research Desk · updated Oct 11, 2026 · data from SEC filings and official Congress disclosures
Insider activity at Nektar Therapeutics has been all selling for a year now: about $2.4 million from three sellers, and zero buyers at market prices.
That's worth context: executives sell for plenty of routine reasons, from scheduled trading plans to tax bills. Buying is the rarer, more telling signal.
Quarter by quarter: 7 quarters in a row of net selling by insiders. Insiders bought in 0 of the last 7 full quarters. 239 investment managers listed NKTR in their latest 13F filings (Q2 2026); more funds bought than sold.
Are insiders buying or selling NKTR stock?
In the last 12 months Nektar Therapeutics insiders made open-market purchases worth about $0 and sales worth about $2.4 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
When was the last insider trade in NKTR?
The most recent open-market insider trade in NKTR was filed on 2026-08-20.
How many institutions own NKTR?
239 investment managers reported holding NKTR in SEC Form 13F filings for Q2 2026.
Has any member of Congress traded NKTR?
No congressional trades in NKTR were reported in the past two years. The full list is free on CapitalSnitch.
Free weekly email: the week's biggest insider buys and Congress trades, every Monday. No spam, one-click unsubscribe.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1).
Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).